United Kingdom (UK)
Recombinant monoclonal antibody to BACE2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1/ 9 .
UniProt Accession Number of Target Protein: Q9Y5Z0
Alternative Name(s) of Target: Beta-secretase 2; Aspartic-like protease; Aspartyl protease 1; Asp1; Beta-site amyloid precursor protein cleaving enzyme 2; Down syndrome aspartic protease; DRAP; Memapsin-1; Membrane-associated aspartic protease 1; theta-secretase
Immunogen: Human BACE2 244–333.
Application Notes: The antibody binds specifically to BACE2, an enzyme responsible for the proteolytic cleavage of amyloid precursor protein (APP). The protein is cleaved between residues 690 and 691, leading to the formation of beta-cleaved soluble APP and a C-terminal membrane bound fragment (CTFβ). The latter is then cleaved by gamma-secretase to generate amyloid beta peptide. BACE is the rate-limiting enzyme in the pathway, and is a potential target in the treatment of Alzheimer's Disease (AD),a neurodegenerative disorder characterised by amyloid beta plaques within the brain. The BACE2 protein is encoded in chromosome 21, in a region critical for the development of Down's Syndrome, and may play a role in the amyloid beta deposition in the disease.
Antibody first published in:
Banner DW, Gsell B, Benz J, Bertschinger J, Burger D, Brack S, Cuppuleri S, Debulpaep M, Gast A, Grabulovski D, Hennig M, Hilpert H, Huber W, Kuglstatter A, Kusznir E, Laeremans T, Matile H, Miscenic C, Rufer AC, Schlatter D, Steyaert J, Stihle M, Thoma R Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr. 2013 Jun;69(Pt 6):1124-37 PMID:23695257
Note on publication:
Describes the role of BACE2 as a potential therapeutic target for the pathogenesis of diabetes and Alzheimer's Disease. Also describes the characterization of the crystal structure of BACE2 with the aid of BACE2-binding antibody Fab fragments.
Immunofluorescence staining of fixed U251 cells with anti-BACE2 antibody 1/9 (Ab00481) Immunofluorescence analysis of paraformaldehyde fixed U251 cells permeabilized with 0.15% Triton and stained with the chimeric mouse IgG1 version of 1/9 (Ab00481-1.1) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (2 µg/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00481-1.1, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-unknown specificity antibody (Ab178-1.1) followed by Alexa Fluor® 488 secondary antibody.
Western Blot using anti-BACE2 antibody 1/9 (Ab00481) HeLa (A) and U251 (B) cell lysate samples (35µg protein in RIPA buffer) were resolved on a 10% SDS PAGE gel and blots probed with the chimeric mouse IgG1 version of 1/9 (Ab00481-1.1) at 1 µg/ml before detection using an anti-mouse secondary antibody. A primary incubation of 1h was used and protein was detected by chemiluminescence. The predicted running size for BACE2 is 56.2 kDa. Ab00481-1.1 successfully detected BACE2 in HeLa and U251 cell lysate samples.
Immunofluorescence staining of fixed U251 cells with anti-BACE2 antibody 1/9 (Ab00481) Immunofluorescence analysis of paraformaldehyde fixed U251 cells permeabilized with 0.15% Triton and stained with the chimeric mouse IgG1 version of 1/9 (Ab00481-1.1) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (2 µg/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00481-1.1, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-unknown specificity antibody (Ab178-1.1) followed by Alexa Fluor® 488 secondary antibody.